The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALS Over 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not
(Financial Post, 2025-12-22T16:20:46Z)